



Genetic Analysis to attend DDW congress in Chicago

OSLO, NORWAY, April 30, 2026: Microbiome DX company Genetic Analysis AS (“GA”) announces its attendance at Digestive Disease Week (DDW) congress in Chicago, May 3 – May 5 2026. The company will use the meeting to highlight its upcoming product, GA-map® IBD Precision Dx, a next-generation diagnostic solution for personalized management in inflammatory bowel disease (IBD).

DDW offers an opportunity to gain the latest insights in the Gastrointestinal field, while providing valuable networking and partnering opportunities. Genetic Analysis’ Head of Commercial, Kari Furu, Christina Casén, SVP Clinical, and Medical and Zuzanna Gulczynska, Product & Marketing Manager, will attend the congress.

GA will use the event to highlight how GA’s microbiome testing platform, GA-map®, can be used for the discovery of novel microbiome-based biomarkers and development of new precision medicine strategies. Specifically, GA will showcase its pipeline product, the GA-map® IBD Precision Dx, the first microbiome-based biomarker for early Ulcerative Colitis (UC) patient stratification. The test enables identification of a microbiome profile associated with aggressive disease, thereby providing prognostic guidance and aid in treatment planning.

Genetic Analysis will also contribute to the scientific program during the meeting:

Sunday, May 3 – 8:00 AM

Kari Furu will give a short presentation introducing Genetic Analysis and our work in gut microbiome innovation during a session hosted by the American Gastroenterological Association (AGA) Gut Microbiome Center and Committee for GI Innovation and Technology.

Monday, May 4 – Poster Session (12:30 - 1:30 PM) | Poster Mo1428

Ken Blount (Ferring Pharmaceuticals), together with Christina Casén, will present our collaborative work with Ferring Pharmaceuticals on: “Monitoring Gut Microbiome Restoration in Patients With Antibiotic-Associated *C. difficile* Infection”.

Attendance at DDW provides an important platform to engage with key stakeholders and supports the company’s ongoing efforts to advance its microbiome-based diagnostics pipeline.

Visit this link to read more about the DDW congress: <https://ddw.org/>

For more information about GA, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

About Genetic Analysis

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiome testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.

For more information: www.genetic-analysis.com

Interested in reading more about GA’s products? Please visit ga-map.com